Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Awakn Life Sciences Corp
(OP:
AWKNF
)
0.0768
-0.0082 (-9.65%)
Streaming Delayed Price
Updated: 11:48 AM EST, Dec 2, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Awakn Life Sciences Corp
< Previous
1
2
3
4
5
Next >
Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
October 15, 2024
Awakn Life Sciences partners with the University of Nottingham to advance in vivo testing of its aminoindane therapy for PTSD, with results expected by late 2024.
Via
Benzinga
Investors Back Awakn's Psychedelic Therapies, As Company Doubles Private Placement To $2M
September 18, 2024
Awakn Life Sciences expands its private placement to $2 million, closing the fourth tranche with $394,286 raised to accelerate research into addiction treatments.
Via
Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Via
Benzinga
Psyched: Biden Approves Psychedelics Trials, RFK, Australia's First Legal Dedicated Clinic & More
December 27, 2023
President Biden Approves Psychedelics Clinical Trials For Active Military Members President Biden signed into law the 2024 National Defense Authorization Act (NDAA), large-scale legislation that also...
Via
Benzinga
Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation
December 21, 2023
Awakn Life Sciences (OTC: AWKNF), a clinical-stage biotechnology company specializing in the development of ketamine-assisted treatments for addiction, has enter
Via
Benzinga
Psyched: Ramaswamy Psychedelics For PTSD, UK Clinical Trials, Johns Hopkins Q&A And More
November 24, 2023
GOP Candidate Vivek Ramaswamy Wants Legal Psychedelics And Cannabis For PTSD In New Veterans Plan
Via
Benzinga
Topics
Cannabis
Exposures
Cannabis
UK Psychedelics: Phase 3 Depression & Alcohol Addiction Trials, New London Center
November 15, 2023
The U.K. Medicines and Healthcare Regulatory Agency (MHRA) has green-lighted two separate Phase 3 trials conducted by Compass Pathways (NASDAQ: CMPS) for Treatment-Resistant Depression and Awakn Life...
Via
Benzinga
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
October 15, 2023
Professor David Nutt, a cognitive sciences, addiction, cannabis and psychedelics researcher, has been ranked the #1 psychopharmacologist by ScholarGPS, a California-based American company owned and...
Via
Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
September 11, 2023
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
September 06, 2023
Awakn Life Sciences Corp. (OTC: AWKNF), a biotech firm focused on developing therapies for addiction, with a primary emphasis on Alcohol Use Disorder (AUD), has taken a big step toward Phase III...
Via
Benzinga
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
August 14, 2023
First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published
Via
Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
August 03, 2023
A Revolutionary Approach: Portugal Decriminalizes Synthetic Drugs Portugal’s Parliament recently decriminalized the use of synthetic drugs. The new law equates the legal treatment of these substances...
Via
Benzinga
Awakn Life Sciences Becomes Pure R&D Biotech After Sale Of Norway Clinics
August 01, 2023
As part of its business restructuring process and following its London clinics busin
Via
Benzinga
Awakn Life Sciences On Track With Phase 3 Trial To Research Substance Use Disorder
July 26, 2023
On this new Psychedelics Exclusive podcast, TDR Founder Shadd Dales interviews Awakn Life Sciences Corp. (OTC: AWKNF) CEO Anthony Tennyson, as his company moves closer towards a Phase III clinical...
Via
Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
July 11, 2023
First Country Allowing MDMA & Psilocybin For Depression, PTSD Makes Headlines On Saturday, July 1, 2023, Australia became the first country to allow physicians to prescribe MDMA to treat post-traumatic...
Via
Benzinga
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next
July 05, 2023
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) sold its London subsidiary and healthcare clinic.
Via
Benzinga
Awakn Life Sciences Announces Closing Of Second Tranche And Upsizing Of Previous Private Placement
June 15, 2023
UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) announced the closing of the second tranche of its latest non-brokered private placement as well as an upsizing of the original...
Via
Benzinga
Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
June 12, 2023
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of...
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
April 28, 2023
The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Severe Alcohol Use Disorder Patients Will Try Ketamine Therapy At Awakn's New Phase 3 Study
April 19, 2023
The research partnership between UK-based psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) and the University of Exeter for an upcoming
Via
Benzinga
EXCLUSIVE: MDMA Therapy Experts Debate Upcoming Approval And Psychedelic Market Opps
April 19, 2023
In the current psychedelics landscape, one of the most important topics is compound legality. While it's possible that MDMA-assisted therapy will eventually be federally approved in the U.S., what...
Via
Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Via
Benzinga
Awakn's Psychedelics Medical Chief Steps Down, Shifts In Company's Stocks And Ownership
April 14, 2023
Awakn Life Sciences Corp. (OTCQB: AWKNF), the biotech company developing psychedelic therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD) shared its recent corporate...
Via
Benzinga
EXCLUSIVE: Ketamine Therapy Provider Nushama Co-Founder On Shifting From A Consciousness Of Blame Into A Space Of Responsibility
March 19, 2023
In light of the latest news regarding the DEA’s telehealth regulations and the
Via
Benzinga
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
March 13, 2023
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll...
Via
Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.